TY  - BOOK
AU  - Lipinski, Michael J
AU  - Van Taunay, John S
TI  - Biologics and Cardiovascular Disease
SN  - 0160-2446
PY  - 2018///
KW  - *Anti-Inflammatory Agents/ad [Administration & Dosage]
KW  - *Biological Products/ad [Administration & Dosage]
KW  - *Cardiovascular Agents/ad [Administration & Dosage]
KW  - *Cardiovascular Diseases/dt [Drug Therapy]
KW  - *Cytokines/ai [Antagonists & Inhibitors]
KW  - *Inflammation Mediators/ai [Antagonists & Inhibitors]
KW  - Animals
KW  - Anti-Inflammatory Agents/ae [Adverse Effects]
KW  - Biological Products/ae [Adverse Effects]
KW  - Cardiotoxicity
KW  - Cardiovascular Agents/ae [Adverse Effects]
KW  - Cardiovascular Diseases/ge [Genetics]
KW  - Cardiovascular Diseases/im [Immunology]
KW  - Cardiovascular Diseases/me [Metabolism]
KW  - Cytokines/im [Immunology]
KW  - Cytokines/me [Metabolism]
KW  - Humans
KW  - Inflammation Mediators/im [Immunology]
KW  - Inflammation Mediators/me [Metabolism]
KW  - Liposomes
KW  - Proprotein Convertase 9/ge [Genetics]
KW  - RNA, Small Interfering/tu [Therapeutic Use]
KW  - RNAi Therapeutics/mt [Methods]
KW  - Signal Transduction/de [Drug Effects]
KW  - Treatment Outcome
KW  - MedStar Heart & Vascular Institute
KW  - Journal Article
N1  - Available online from MWHC library: 1996 - present
N2  - The advent of biologic therapy has enhanced our ability to augment disease in an increasingly targeted manner. The use of biologics in cardiovascular disease (CVD) has steadily increased over the past several decades. Much of the early data on biologics and CVD were derived from their use in rheumatologic populations. Atherosclerosis, myocardial infarction, and heart failure have been closely linked to the inflammatory response. Accordingly, cytokines such as tumor necrosis factor (TNF)-alpha and interleukin (IL)-1 have been targeted. Non-inflammatory mediators, such as proprotein convertase subtilisin kexin type 9 (PCSK9), have been selected for therapeutic intervention as well. Furthermore, RNA interference (RNAi) therapy has emerged and may serve as another targeted therapeutic mechanism. Herein, we will review the history, obstacles, and advances in utilizing biologic therapy for CVD
UR  - https://dx.doi.org/10.1097/FJC.0000000000000595
ER  -